SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 5,492.08 |
Enterprise Value ($M) | 6,032.21 |
Book Value ($M) | 298.67 |
Book Value / Share | 4.67 |
Price / Book | 18.39 |
NCAV ($M) | -138.47 |
NCAV / Share | -2.17 |
Price / NCAV | -39.66 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.07 |
Return on Assets (ROA) | -0.06 |
Return on Equity (ROE) | -0.22 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.80 |
Current Ratio | 2.85 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 742.68 |
Assets | 1,179.81 |
Liabilities | 881.15 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 508.82 |
Operating Income | -212.04 |
Net Income | -67.09 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -192.59 |
Cash from Investing | -47.50 |
Cash from Financing | 273.11 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Fmr Llc | 3.50 | -48.31 | |
13G/A | Price T Rowe Associates Inc /md/ | 8.50 | -13.82 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
146,949 | 831,475 | 17.67 | |
350,007 | 1,126,416 | 31.07 | |
307,423 | 995,634 | 30.88 | |
112,909 | 382,836 | 29.49 | |
(click for more detail) |
Similar Companies | |
---|---|
BLUE – bluebird bio, Inc. | BMEA – Biomea Fusion, Inc. |
BMRN – BioMarin Pharmaceutical Inc. | CABA – Cabaletta Bio, Inc. |
CCCC – C4 Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io